Panagiotis Zis1, André Strydom2, David Buckley3, Daniel Adekitan3, Patrick C McHugh3. 1. University College London, Division of Psychiatry, London, United Kingdom; Sheffield Teaching Hospitals NHS Trust, Department of Neurology, Sheffield, United Kingdom. Electronic address: takiszis@gmail.com. 2. University College London, Division of Psychiatry, London, United Kingdom; The LonDowns Consortium, United Kingdom. 3. Centre for Biomarker Research, School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.
Abstract
BACKGROUND: Neopterin is an unconjugated pteridine that is secreted in large quantities by activated macrophages and can be used as a clinical marker of activated cellular immunity and oxidative stress. We aimed to investigate whether urinary neopterin levels are associated with cognitive function in people with Down syndrome (DS). METHODS: Out of 32 adults with DS who originally participated in a longitudinal study, 25 were followed up at 4 years. Informants rated their adaptive behavior (ABAS) and the adults with DS attempted assessments of language skills and memory at both baseline and follow-up time points (Modified Memory Object Task, MOMT), and receptive vocabulary (British Picture Vocabulary Scale, BPVS). RESULTS: Neopterin/creatinine levels were negatively correlated with change in the MOMT total score (Spearman's Rho=-0.517, p=0.020) and change in the MOMT delayed recall score (Spearman's Rho=-0.577, p=0.008) over time, i.e. higher neopterin/creatinine level was associated with worse performance on a test of cognitive ability over time. CONCLUSION: Urine neopterin may have potential as a biomarker for memory decline in Down syndrome, and could potentially also help to track progression of mild cognitive impairment (MCI) to Alzheimer's disease in other high risk populations. Copyright Â
BACKGROUND:Neopterin is an unconjugated pteridine that is secreted in large quantities by activated macrophages and can be used as a clinical marker of activated cellular immunity and oxidative stress. We aimed to investigate whether urinary neopterin levels are associated with cognitive function in people with Down syndrome (DS). METHODS: Out of 32 adults with DS who originally participated in a longitudinal study, 25 were followed up at 4 years. Informants rated their adaptive behavior (ABAS) and the adults with DS attempted assessments of language skills and memory at both baseline and follow-up time points (Modified Memory Object Task, MOMT), and receptive vocabulary (British Picture Vocabulary Scale, BPVS). RESULTS:Neopterin/creatinine levels were negatively correlated with change in the MOMT total score (Spearman's Rho=-0.517, p=0.020) and change in the MOMT delayed recall score (Spearman's Rho=-0.577, p=0.008) over time, i.e. higher neopterin/creatinine level was associated with worse performance on a test of cognitive ability over time. CONCLUSION: Urine neopterin may have potential as a biomarker for memory decline in Down syndrome, and could potentially also help to track progression of mild cognitive impairment (MCI) to Alzheimer's disease in other high risk populations. Copyright Â
Authors: Jonathan D Santoro; Rebecca Partridge; Runi Tanna; Dania Pagarkar; Mellad Khoshnood; Mustafa Rehmani; Ryan M Kammeyer; Grace Y Gombolay; Kristen Fisher; Allison Conravey; Jane El-Dahr; Alison L Christy; Lina Patel; Melanie A Manning; Heather Van Mater; Michael S Rafii; Eileen A Quinn Journal: J Neurodev Disord Date: 2022-06-03 Impact factor: 4.074
Authors: Marina P Sánchez; Ana M García-Cabrero; Gentzane Sánchez-Elexpuru; Daniel F Burgos; José M Serratosa Journal: Int J Mol Sci Date: 2018-04-05 Impact factor: 5.923
Authors: Carla M Startin; Nicholas J Ashton; Sarah Hamburg; Rosalyn Hithersay; Frances K Wiseman; Kin Y Mok; John Hardy; Alberto Lleó; Simon Lovestone; Lucilla Parnetti; Henrik Zetterberg; Abdul Hye; André Strydom Journal: Alzheimers Res Ther Date: 2019-03-21 Impact factor: 6.982
Authors: Andre Strydom; Amanda Heslegrave; Carla M Startin; Kin Y Mok; John Hardy; Jurgen Groet; Dean Nizetic; Henrik Zetterberg Journal: Alzheimers Res Ther Date: 2018-04-10 Impact factor: 6.982
Authors: James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi Journal: Transl Sci Rare Dis Date: 2021-04-15